View in EDS HTML Full Text PDF Full Text

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Saved in:
Bibliographic Details
Title: A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Authors: Leblond, Véronique1 (AUTHOR), Morel, Pierre2,3,4 (AUTHOR) pimorel@nordnet.fr, Dilhuidy, Marie-Sarah5 (AUTHOR), Leleu, Xavier6 (AUTHOR), Soussain, Carole7,8 (AUTHOR), Leprête, Stéphane9 (AUTHOR), Dreyfus, Brigitte10 (AUTHOR), Dartigeas, Caroline11 (AUTHOR), Mahé, Béatrice12 (AUTHOR), Anglaret, Bruno13 (AUTHOR), Pégourié, Brigitte14 (AUTHOR), Besson, Caroline15 (AUTHOR), Aurran, Thérèse16 (AUTHOR), Vekhoff, Anne17 (AUTHOR), Tournilhac, Olivier18 (AUTHOR), Banos, Anne19 (AUTHOR), Oya, Hervé20 (AUTHOR), Lejeune, Julie21 (AUTHOR), Ouzegdouh, Maya1 (AUTHOR), Chevret, Sylvie21 (AUTHOR)
Source: Leukemia & Lymphoma. 2017, Vol. 58 Issue 11, p2615-2623. 9p. 1 Diagram, 2 Charts, 4 Graphs.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2017.1307357